



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Jussi TOMPERI et al.

Application No.: 10/574,584

Filed: April 4, 2006

Docket No.: 117373

For: SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND
ANTAGONISTS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- ☒ 2. In accordance with 37 CFR §1.98(a)(2)(ii), copies of any U.S. patents and patent application publications are not attached.
- ☒ 3. An English language Abstract of one or more non-English language reference is attached hereto. See Reference 15.

Respectfully submitted,

James A. Oliff

Registration No. 27,075

Kristin K. Vidovich

Registration No. 41,448

JAO:KKV/smo

Date: August 21, 2006

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

**DEPOSIT ACCOUNT USE
AUTHORIZATION**

Please grant any extension
necessary for entry;
Charge any fee due to our
Deposit Account No. 15-0461

Sheet 1 of 3Form PTO-1449
(REV. 1/06)US Dept. of Commerce
PATENT & TRADEMARK OFFICEATTY DOCKET NO.
117373APPLICATION NO.
10/574,584

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT(S)
Jussi TOMPERI et al.FILING DATE
April 4, 2006

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Date	Name
	1.	6,124,256	9/26/2000	Hayry et al.
	2.	6,221,870	4/24/2001	Pfaeffli et al.
	3.	4,485,101	11/27/1984	Coy et al.
	4.	5,409,894	4/25/1995	Handley
	5.	6,329,389	12/11/2001	Suzuki et al.
	6.	6,352,982	3/5/2002	Mabuchi et al.
	7.	6,271,252	8/7/2001	Chang et al.
	8.	6,221,888	4/24/2001	Durette et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation
	9.	WO 98/53818	12/3/1998	WIPO		
	10.	EP 0 183 271 A2	6/4/1986	Europe		
	11.	WO 97/03054	1/30/1997	WIPO		
	12.	WO 97/47317	12/18/1997	WIPO		
	13.	WO 97/14715	4/24/1997	WIPO		
	14.	WO 97/43278	11/20/1997	WIPO		
	15.	WO 02/24192 A1	3/28/2002	WIPO	X	
	16.	WO 03/026575 A2	4/3/2003	WIPO		

OTHER DOCUMENTS

	17.	Bonini, J.A. et al., "Identification and Characterization of Two G Protein-coupled Receptors for Neuropeptide FF," <i>Journal of Biological Chemistry</i> 275(50): 39324-39331 (December 2000)

EXAMINER

DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date: August 21, 2006

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 117373		APPLICATION NO. 10/574,584	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT(S) Jussi TOMPERI et al.			
				FILING DATE April 4, 2006			
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Name			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation	
OTHER DOCUMENTS							
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)					
	18.	Reubi, J.C. et al., "A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors," <i>European Journal of Pharmacology</i> 345: 103-110 (1998)					
	19.	Reubi, J.C. et al., "Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands," <i>European Journal of Nuclear Medicine</i> 28(7): 836-846 (July 2001)					
	20.	Rivier, J.E. et al., "Potent Somatostatin Undecapeptide Agonists Selective for Somatostatin Receptor 1 (sst1)," <i>Journal of Medicinal Chemistry</i> 44(13): 2238-2246 (2001)					
	21.	Sinisi, A.A. et al., "Different Expression Patterns of Somatostatin Receptor Subtypes in Cultured Epithelial Cells from Human Normal Prostate and Prostate Cancer," <i>Journal of Clinical Endocrinology and Metabolism</i> 82(8): 2566-2569 (1997)					
	22.	von Essen, R. et al., "Effects of Octreotide Treatment on Restenosis After Coronary Angioplasty: Results of the VERAS Study," <i>Circulation</i> 96(5): 1482-1487 (September 1997)					
	23.	Yang, H.-Y.T. et al., "Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine," <i>Proc. National Academy of Science USA</i> 82: 7757-7761 (November 1985)					
	24.	Hoyer, D. et al., "Classification and nomenclature of somatostatin receptors," <i>TIPS</i> 16: 86-88 (March 1995)					
	25.	Mazarguil, H. et al., "Structure-activity relationships of neuropeptide FF: role of C-terminal regions," <i>Peptides</i> 22: 1471-1478 (2001)					
	26.	Mori, M. et al., "Differential expression of somatostatin receptors in the rat eye: SSTR4 is intensely expressed in the iris/ciliary body," <i>Neuroscience Letters</i> 223: 185-188 (1997)					
	27.	Patel, Y.C., "Somatostatin and Its Receptor Family," <i>Frontiers in Neuroendocrinology</i> 20: 157-198 (1999)					
	28.	Payza, K. et al., "Neuropeptide FF Receptors: Structure-Activity Relationship and Effect of Morphine," <i>Journal of Pharmacology and Experimental Therapeutics</i> 267(1): 88-94 (1993)					
	29.	Reisine, T. et al., "Molecular Biology of Somatostatin Receptors," <i>Endocrine Reviews</i> 16(4): 427-442 (August 1995)					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: August 21, 2006

Form PTO-1449 (REV. 1/06)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 117373		APPLICATION NO. 10/574,584	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT(S) Jussi TOMPERI et al.			
				FILING DATE April 4, 2006			
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Name			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation	
OTHER DOCUMENTS							
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)					
	30.	Bourguignon, J.J. et al., "Analogues of NPFF, a neuropeptide which modulates morphine analgesia," <i>Proceedings of the XIVth International Symposium on Medicinal Chemistry</i> , pp. 35-44 (1997) (Elsevier Science B.V.)					
	31.	Brussaard, A.B. et al., "Peripheral Injection of DNS-Injection RFa, A FMRFa Agonist, Suppresses Morphine-Induced Analgesia in Rats," <i>Peptides 10: 735-739</i> (1989)					
	32.	Cheng, Y.-C. et al., "Relationship between the Inhibition Constant (K_i) and the Concentration of Inhibitor which Causes 50 Per Cent Inhibition (I_{50}) of an Enzymatic Reaction," <i>Biochemical Pharmacology 22: 3099-3108</i> (1973)					
	33.	Curtis, S.B. et al., "Somatostatin receptor subtype expression and function in human vascular tissue," <i>Am. J. Physiol. Heart Circ. Physiol. 278: H1815-H1822</i> (2000)					
	34.	Eriksen, U.H. et al., "Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty," <i>American Heart Journal 130(1): 1-8</i> (July 1995)					
	35.	Gicquel, S. et al., "Structure-Activity Study of Neuropeptide FF: Contribution of N-Terminal Regions to Affinity and Activity," <i>Journal of Medicinal Chemistry 37(21): 3477-3481</i> (1994)					
	36.	Rohrer, S.P. et al., "Rapid Identification of Subtype-Selective Agonists of the Somatostatin Receptor Through Combinatorial Chemistry," <i>Science 282: 737-740</i> (October 1998)					
	37.	Aavik, E. et al., "Elimination of vascular fibrointimal hyperplasia by somatostatin receptor 1,4-selective agonist," <i>FASEB Journal 16: 724-726</i> (May 2002)					
	38.	Bito, H. et al., "Functional Coupling of SSTR4, a Major Hippocampal Somatostatin Receptor, to Adenylate Cyclase Inhibition, Arachidonate Release, and Activation of the Mitogen-activated Protein Kinase Cascade," <i>Journal of Biological Chemistry 269(17): 12722-12730</i> (April 1994)					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: August 21, 2006